The Global Achievement Award recognizes University of Ottawa Heart Institute (UOHI) investigators who have demonstrated the potential to be a global leader, or have made a global impact in his/her sphere of work. The selection panel is comprised of the CEO/President, the Chief Scientific Officer/VP Research, and the four Division Chiefs.
This year, the award goes to Dr. David Birnie, an international leader in cardiac sarcoidosis research. A passionate and committed physician researcher, Dr. Birnie has enabled UOHI success on the international stage in this area of research, including establishing the Cardiac Sarcoidosis Clinical Trial and Registry. He played a pivotal role in the development of the first Canadian Cardiovascular Society (CCS) guidelines for cardiac resynchronization therapy in 2013, and the 2016 update to guidelines for ICD implantation. Dr. Birnie is the Chair of the Heart Rhythm Society Expert Consensus Statement Panel.
Dr. Birnie has published ~200 peer reviewed publications, most notably the BRUISE CONTROL trial in the New England Journal of Medicine in 2013, and recently the BRUISE CONTROL INFECTION in the Journal of the American College of Cardiology. He has been awarded millions of dollars in peer reviewed as well as industry funding. Dr. Birnie is a Mid Career Investigator supported by a salary award from the Heart and Stroke Foundation. Dr. Birnie currently co-leads the large-scale randomized controlled trial known as OCEAN - to compare oral anti-coagulant with rivaroxaban to aspirin after successful AF ablation in reducing the risk of stroke.